Generic pharmaceutical company Mylan N.V. (MYL) today officially announced a reduction in the approval requirement for the Perrigo Company (NYSE:PRGO; TASE:PRGO) deal from 80% to 50%. This means that under certain circumstances, Mylan could settle for acquiring control of Perrigo, without acquiring full ownership of the company.
Read the full story, click here
Published by Globes [online], Israel business news – www.globes-online.com
